Volume 30, Number 11—November 2024
CME ACTIVITY - Research
Extrapulmonary Mycobacterium abscessus Infections, France, 2012–20201
Benoît Heid-Picard
, Faiza Mougari, Anne Pouvaret, Fanny Lanternier, Zeina Awad, Emmanuelle Bille, Olivier Lortholary2, Emmanuelle Cambau2, and the Mabsc Study Group3
, Faiza Mougari, Anne Pouvaret, Fanny Lanternier, Zeina Awad, Emmanuelle Bille, Olivier Lortholary2, Emmanuelle Cambau2, and the Mabsc Study Group3
Table
Characteristics of 45 extrapulmonary Mycobacterium abscessus infections, France, 2012–2020*
| Variable |
Infections |
Total |
||
|---|---|---|---|---|
| Bone/joint |
Skin/soft tissue |
Lymph node |
||
| Patients, no. (%) | 14 (30) | 10 (22) | 8 (18) | 45 (100) |
| Mean age, y, ± SD | 50.2 ± 26.6 | 60.8 ± 21.2 | 43.7 ± 25.3 | 51.4 ± 24.5 |
| M/F sex ratio |
1.33 |
0.66 |
1 |
0.88 |
| Geographic origin, no. (%) | ||||
| Metropolitan France | 3 | 4 | 2 | 13 (29) |
| Overseas French territories | 4 | 3 | 2 | 13 (29) |
| Foreign countries |
7 |
3 |
4 |
19 (42) |
| Underlying immune disorder, no. (%) | ||||
| No known immunodeficiency | 13 | 4 | 5 | 28 (62) |
| Immunosuppressive treatment | 1 | 5 | 2 | 9 (20) |
| Solid tumor | 0 | 0 | 1 | 4 (9) |
| Malignant hemopathy |
0 |
1 |
0 |
2 (4) |
| Clinical features, no. (%) | ||||
| B symptoms† | 7 | 4 | 2 | 17 (38) |
| Skin involvement |
4 |
10 |
2 |
22 (49) |
| Initial injury | 12 | 3 | 3 | 27 (60) |
| Median months to diagnosis [range] | 4.5 [0.25–72] | 1.5 [1–72] | 1 [0.25–3] | 3 [0.25–72] |
| Environmental | 4 | 1 | 2 | 7 (16) |
| Healthcare associated |
8 |
2 |
1 |
20 (44) |
| M. abscessus subspecies and erm(41) sequevars, no. (%) | ||||
| abscessus T28 | 7 | 5 | 1 | 19 (40) |
| abscessus C28 | 2 | 1 | 0 | 6 (13) |
| bolletii | 2 | 2 | 4 | 12 (26) |
| massiliense |
3 |
2 |
2 |
9 (19) |
| Medical management, no. (%) | ||||
| Surgery + antimicrobial regimen | 11 | 3 | 3 | 22 (49) |
| Surgery alone | 1 | 0 | 1 | 3 (7) |
| Antimicrobial regimen alone | 2 | 6 | 3 | 13 (29) |
| Media months of antimicrobial regimen duration [range] |
6 [2–12] |
6 [3–15] |
6 [1–6] |
6 [1–long-term] |
| Outcome, no. (%) | ||||
| Cure | 13 | 7 | 7 | 33 (73) |
| Relapse then cured | 0 | 0 | 0 | 3 (7) |
| Not available for follow-up | 1 | 2 | 1 | 5 (11) |
| Death | 0 | 1 | 0 | 4 (9) |
*Values are no. (%) except as indicated. †Fever, night sweats, or weight loss.
1Preliminary results from this study were displayed as oral communications at the 31st European Congress of Clinical Microbiology and Infectious Diseases (July 9–12, 2021, Vienna, Austria; abstract no. 04396) and at the 24èmes Journées Nationales d’Infectiologie (June 7–9, 2023, Grenoble, France; abstract no. PADS02-03).
2These authors contributed equally to this article.
3Mabsc Study Group members are listed at the end of this article.
Page created: September 30, 2024
Page updated: October 21, 2024
Page reviewed: October 21, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.